11 completed, 4 recruiting, 2 active not recruiting, 2 terminated. 14 Phase 1, 12 Phase 2, 1 Phase 3.
Follow AC220: new trials by email Literature Review of AC220 trials Research Report on AC220
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-30 |
| CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients Quizartinib, Etoposide, Dexrazoxane - Acute Myeloid Leukemia in Children | Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 60 | 2024-02-06 | 2025-08-05 |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Azacitidine, Quizartinib - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2020-07-21 | 2026-10-05 |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Liposome-encapsulated Daunorubicin-Cytarabine, Quizartinib - Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 52 | 2020-05-27 | 2026-06-02 |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cladribine, Cytarabine, Idarubicin - Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2019-10-22 | 2026-06-12 |
| Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia Quizartinib, Venetoclax - Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2019-01-25 | 2024-09-19 |
| Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Quizartinib, Milademetan - Acute Myeloid Leukemia | Phase 1 | Terminated | Daiichi Sankyo | 10 | 2018-12-12 | 2022-05-20 |
| Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Quizartinib - Acute Myeloid Leukemia (AML) | Phase 1 | Completed | Daiichi Sankyo Co., Ltd. | 7 | 2018-11-05 | 2022-07-29 |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Decitabine, Quizartinib, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 73 | 2018-10-31 | 2026-09-24 |
| Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD Quizartinib, Omacetaxine Mepesuccinate Injection - AML, FLT3-ITD Mutation | Phase 2 | Unknown | The University of Hong Kong | 40 | 2017-10-01 | 2020-12-10 |
| Phase 1 Study of Quizartinib AC220 - Relapsed AML, Refractory AML | Phase 1 | Completed | Daiichi Sankyo Co., Ltd. | 17 | 2016-02-01 | 2019-02-12 |
| (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Quizartinib, Salvage Chemotherapy - AML | Phase 3 | Completed | Daiichi Sankyo | 367 | 2014-05-01 | 2021-02-24 |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Quizartinib - FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 73 | 2013-11-12 | 2026-10-23 |
| Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia laboratory biomarker analysis, quizartinib, sorafenib tosylate - Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies | Completed | Children's Oncology Group | 10 | 2012-05-01 | 2016-05-17 | |
| Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia AC220 - Leukemia, Myeloid, Acute | Phase 2 | Completed | Daiichi Sankyo | 76 | 2012-04-01 | 2019-12-27 |
| A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) AC220 - Leukemia, Myeloid, Acute | Phase 1 | Completed | Daiichi Sankyo | 13 | 2012-04-01 | 2019-02-12 |
| A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) AC220, daunorubicin, cytarabine - Leukemia, Myeloid, Acute | Phase 1 | Completed | Daiichi Sankyo | 19 | 2011-10-01 | 2019-02-12 |
| AC220 for Children With Relapsed/Refractory ALL or AML AC220, Cytarabine, Etoposide - Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood | Phase 1 | Completed | Therapeutic Advances in Childhood Leukemia Consortium | 24 | 2011-09-01 | 2022-04-04 |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. Plerixafor, AC220, Ganetespib - Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Cardiff University | 113 | 2011-04-01 | 2014-06-11 |
Showing 20 of 21. Sign in to see all of them.
Leukemia, Myeloid, Acute (17) · Myelodysplastic Syndromes (6) · Leukemia (4) · Recurrence (4) · Leukemia, Myelomonocytic, Chronic (2) · Myeloproliferative Disorders (2) · Aortic aneurysm, familial thoracic 4 (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Myeloid (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1)
Daiichi Sankyo (6) · M.D. Anderson Cancer Center (6) · Daiichi Sankyo Co., Ltd. (2) · National Cancer Institute (NCI) (2) · Cardiff University (1) · Children's Oncology Group (1) · Princess Maxima Center for Pediatric Oncology (1) · The University of Hong Kong (1) · Therapeutic Advances in Childhood Leukemia Consortium (1)
United States (15) · United Kingdom (3) · Canada (2) · France (2) · Hong Kong (2) · Italy (2) · Netherlands (2) · Australia (1) · Belgium (1) · China (1) · Croatia (1) · Czechia (1) · Georgia (1) · Germany (1) · Hungary (1)
Musa Yilmaz (3) · Guy Gammon, MB, BS, MRCP (2) · Alan K Burnett (1) · Anskar Leung, Professor (1) · Gertjan Kaspers, Prof. Dr. (1) · Guillermo M Bravo (1) · Jerald P Radich (1) · Jorge E. Cortes, MD (1) · Keith W Pratz (1) · Michel Zwaan, Prof. Dr. (1) · Naval G Daver (1) · Nigel H Russell (1)
PMID 24002496, PMID 26920889, PMID 29859851, PMID 31175001, PMID 31359361, PMID 33208914, PMID 33415416, PMID 36902217, PMID 38744144, PMID 40327322, PMID 42321916
2023 (1), U10CA180820 (1), U10CA180888 (1)